PreveCeutical Medical Inc
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its research and development programs include dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical peptides for treatment of various ailments; nonaddict… Read more
PreveCeutical Medical Inc (PRVCF) - Net Assets
Latest net assets as of September 2025: $-7.39 Million USD
Based on the latest financial reports, PreveCeutical Medical Inc (PRVCF) has net assets worth $-7.39 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($456.04K) and total liabilities ($7.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-7.39 Million |
| % of Total Assets | -1621.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -5998.69% |
| Growth Volatility | 282.41 |
PreveCeutical Medical Inc - Net Assets Trend (2015–2024)
This chart illustrates how PreveCeutical Medical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PreveCeutical Medical Inc (2015–2024)
The table below shows the annual net assets of PreveCeutical Medical Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-6.64 Million | -14.86% |
| 2023-12-31 | $-5.78 Million | -24.66% |
| 2022-12-31 | $-4.64 Million | -12.94% |
| 2021-12-31 | $-4.10 Million | -13.88% |
| 2020-12-31 | $-3.60 Million | +19.68% |
| 2019-12-31 | $-4.49 Million | -96.34% |
| 2018-12-31 | $-2.29 Million | -563.64% |
| 2017-12-31 | $-344.34K | -16.31% |
| 2016-12-31 | $-296.06K | -363.13% |
| 2016-07-31 | $112.52K | +201.70% |
| 2015-12-31 | $37.29K | -- |
Equity Component Analysis
This analysis shows how different components contribute to PreveCeutical Medical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2951248200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $22.92 Million | % |
| Total Equity | $-6.64 Million | 100.00% |
PreveCeutical Medical Inc Competitors by Market Cap
The table below lists competitors of PreveCeutical Medical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pan American Energy Corp
OTCQB:PAANF
|
$5.87 Million |
|
AVENSIA AB SK -15
F:5IY
|
$5.87 Million |
|
Samyoung S&C Co. Ltd.
KQ:361670
|
$5.87 Million |
|
Honkarakenne Oyj B
HE:HONBS
|
$5.88 Million |
|
REVOLVE RENEW.POWER CORP.
F:PM7
|
$5.87 Million |
|
Cordlife Group Limited
PINK:CLIFF
|
$5.87 Million |
|
Xelpmoc Design And Tech Limited
NSE:XELPMOC
|
$5.87 Million |
|
Jiangsu Zitian Media Technology Co Ltd
SHE:300280
|
$5.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PreveCeutical Medical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -5,778,170 to -6,636,908, a change of -858,738.
- Net loss of 1,174,677 reduced equity.
- New share issuances of 94,697 increased equity.
- Other factors increased equity by 221,242.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.17 Million | -17.7% |
| Share Issuances | $94.70K | +1.43% |
| Other Changes | $221.24K | +3.33% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares PreveCeutical Medical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-07-31 | $0.00 | $0.01 | x |
| 2017-12-31 | $0.00 | $0.01 | x |
| 2018-12-31 | $-0.01 | $0.01 | x |
| 2019-12-31 | $-0.01 | $0.01 | x |
| 2020-12-31 | $-0.01 | $0.01 | x |
| 2021-12-31 | $-0.01 | $0.01 | x |
| 2022-12-31 | $-0.01 | $0.01 | x |
| 2023-12-31 | $-0.01 | $0.01 | x |
| 2024-12-31 | $-0.01 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PreveCeutical Medical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-115.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 1.00x | $-6.13K |
| 2015 | -1319.31% | 0.00% | 0.00x | 3.61x | $-495.75K |
| 2016 | -69.00% | 0.00% | 0.00x | 1.09x | $-88.89K |
| 2016 | 0.00% | -10070.26% | 0.15x | 0.00x | $-3.10 Million |
| 2017 | 0.00% | -32526.24% | 0.01x | 0.00x | $-7.20 Million |
| 2018 | 0.00% | -76909.98% | 0.01x | 0.00x | $-11.66 Million |
| 2019 | 0.00% | -118076.54% | 0.00x | 0.00x | $-3.13 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.44 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.32 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.02 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-696.65K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-510.99K |
Industry Comparison
This section compares PreveCeutical Medical Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PreveCeutical Medical Inc (PRVCF) | $-7.39 Million | 0.00% | N/A | $5.87 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |